- Cardinal Health invites independent pharmacy owners to ‘discover new horizons’ at RBC 2013
- Federal government must find alternatives to rescheduling hydrocodone combination drugs
- FDA to recommend rescheduling of opioid painkiller hydrocodone from CIII to CII
- Study: Antivirals like Tamiflu, Relenza reduce deaths among children critically ill with the flu
- Prestige Brands solution to pediatric overdosing — unique squeezable, single-dose APAP packet
SUMMIT, N.J. — The Food and Drug Administration has approved a drug made by Celgene Corp. for treating a type of cancer.
Celgene announced Thursday the approval of Revlimid (lenalidomide) for treatment of patients with mantle cell lymphoma, also known as MCL, whose disease has relapsed or progressed after two prior therapies that have included bortezomib.
"There remains a tremendous unmet need for patients with previously treated mantle-cell lymphoma," Hackensack, N.J., cancer specialist Andre Goy said in a statement on behalf of Celgene. "This approval of lenalidomide delivers a new option and the first oral therapy in this area of lymphoma."
Are you a nurse practitioner or physician's assistant? Join our Facebook group to get all the latest news dedicated to delivering healthcare services to patients in retail pharmacy clinics.